Gene: CD55
Official Full Name: CD55 molecule (Cromer blood group)provided by HGNC
Gene Summary: This gene encodes a glycoprotein involved in the regulation of the complement cascade. Binding of the encoded protein to complement proteins accelerates their decay, thereby disrupting the cascade and preventing damage to host cells. Antigens present on this protein constitute the Cromer blood group system (CROM). Alternative splicing results in multiple transcript variants. The predominant transcript variant encodes a membrane-bound protein, but alternatively spliced transcripts may produce soluble proteins. [provided by RefSeq, Jul 2014]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO03547 | CD55 Knockout cell line (HeLa) | Human | CD55 | 1:3~1:6 | Negative | Online Inquiry |
KO03548 | CD55 Knockout cell line (HCT 116) | Human | CD55 | 1:2~1:4 | Negative | Online Inquiry |
KO03549 | CD55 Knockout cell line (HEK293) | Human | CD55 | 1:3~1:6 | Negative | Online Inquiry |
KO03550 | CD55 Knockout cell line (A549) | Human | CD55 | 1:3~1:4 | Negative | Online Inquiry |
CD55 Gene Knockout Cell Lines are specifically engineered cell lines that have been genetically modified to disrupt the expression of the CD55 gene, which encodes an important membrane protein that regulates the complement system. This modification provides researchers with a robust tool for studying the biological roles of CD55, facilitating investigations into the complement pathways and their implications in various diseases, including autoimmune disorders, cancers, and infectious diseases.
The key function of CD55 lies in its ability to inhibit the complement system, preventing the unwanted activation of complement proteins that could lead to cell lysis and inflammation. By creating knockout cell lines, researchers can explore the phenotypic effects of CD55 absence, elucidating its role in cellular communications, immune responses, and tumor progression. The resultant data aids in understanding how the modulation of the complement system affects disease states, thereby allowing for the development of targeted therapeutic interventions.
Scientifically, these cell lines hold immense value as they empower both basic and translational research. In clinical settings, a deeper understanding of CD55 could lead to breakthroughs in treatments that harness the immune system to combat cancer or that regulate inflammatory responses to alleviate autoimmune diseases. Compared to traditional wild-type cell lines, our CD55 gene knockout cell lines offer a unique advantage as they provide a clear, unambiguous model to study the consequences of absent CD55 protein expression without interference from additional signaling pathways.
For researchers and clinicians alike, the critical insights gained from utilizing CD55 knockout models can accelerate the pace of innovation in immunotherapy and precision medicine. Our commitment to scientific excellence in product development ensures that customers receive high-quality cell lines supported by rigorous validation processes. Trust in our expertise to provide the tools necessary to advance your research and clinical applications in the field of immunology and beyond.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.